HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Targeted HER2 Treatment in Advanced Gastric Cancer

(2010) Jan Trøst Jørgensen   ONCOLOGY

Chromogenic In Situ Hybridization Is a Reliable Method for DetectingHER2Gene Status in Breast Cancer

(2009) Yun Gong et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

MicroRNA-196a Is a Potential Marker of Progression during Barrett's Metaplasia-Dysplasia-Invasive Adenocarcinoma Sequence in Esophagus

(2009) Dipen M. Maru et al.   AMERICAN JOURNAL OF PATHOLOGY

Chromogenicin situhybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenicin situhybridization with immunohistochemistry and fluorescencein situhybridization

(2009) Doris Mayr et al.   HISTOPATHOLOGY

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY

HER-2 overexpression/amplification in Barrett’s oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study

(2008) Elisa Rossi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE